Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (Pediatric MATCH)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; El-Shami, Jessica; Leffin, Melissa
Trial Phone: 321.841.5357 ; 321.841.3837 ; 321.841.2008
-
IRB No: APEC1621E
Protocol Abbrev: APEC1621E
Principal Investigator: Amy A Smith, MD
Phase: Drug: Phase II
Age Group: Adult;Pediatric
Secondary Protocol No: APEC1621E
Treatment: Other: Laboratory Biomarker Analysis; Drug: Selumetinib; Drug: Selumetinib Sulfate
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03213691
-
Objective
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with selumetinib (AZD6244 hydrogen sulfate) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in the MAPK pathway.
-
Key Eligibility
Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
